Valeo Pharma launches Onstryv for treating Parkinsons disease in Canada

Onstryv is a prescription medication that can now be obtained at pharmacies across Canada and is available in 50mg and 100mg tablets. Valeo Pharma’s national sales team has launched a physician awareness and information campaign which is being supported by marketing and social media activities.

MONTREAL: Valeo Pharma Inc.(“Valeo”), a Canadian specialty pharmaceutical company, recently announced the Canadian launch of Onstryv (safinamide tablets) for the treatment of patients suffering from Parkinson’s Disease. Valeo has the exclusive rights to commercialize Onstryv in Canada under a license agreement signed with Zambon S.p.A.

Valeo previously announced the approval of Onstryv by Health Canada, January 15, 2019, as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson’s Disease in patients experiencing “off” episodes.

Read Also: Alembic Pharma gets USFDA nod for generic version of Tamiflu capsules

Onstryv is a prescription medication that can now be obtained at pharmacies across Canada and is available in 50mg and 100mg tablets. Valeo’s national sales team has launched a physician awareness and information campaign which is being supported by marketing and social media activities.

“The number of Canadians afflicted with Parkinson’s Disease is expected to grow by more than 50% over the next decade as the Canadian population ages” said Steve Saviuk, Chief Executive Officer of Valeo. “Onstryv is the first new oral treatment for Parkinson’s Disease to be approved in Canada in well over a decade. Many patients experience progressive symptom difficulties with currently available treatments and we are proud to bring a new option to address this growing need for Canadian patients. Valeo is committed to building and supporting relationships with healthcare professionals, patients and other stakeholders to build awareness and ensure access to this new treatment for Parkinson’s Disease.”

Roberto Tascione, CEO of Zambon said “Since 1906 Zambon is committed to provide
innovative medicines for patients and doctors and this launch is another significant step forward to fulfill our vision: Innovating Cure & Care to make patients’ lives better.

Right now, with this important milestone, Safinamide has been launched in 14 European Union countries, Switzerland, U.S.A, Australia and Canada and has recently been approved in Brazil, and Colombia.”

Read Also: Alembic Pharma gets USFDA nod for Bromfenac Ophthalmic Solution

Parkinson’s Disease is a progressive neurological disease involving the loss of dopamine producing neurons in the brain. While tremors are the best known symptom, Parkinson’s Disease also causes other symptoms including slowed movement, rigid muscles, impaired posture and balance, speech and writing difficulties. On a per capita basis, Canada has amongst the highest incidences of Parkinson’s Disease in the world and the number of patients is expected to grow significantly over the next thirty years as the median population age increases.